Skip to main content

The Future of FDA and Cannabis Regulation (now available for On-Demand CLE)

Regulation of cannabis by the federal government, specifically the Food & Drug Administration, was unthinkable less than a decade ago, but it will someday soon be a reality. The FDA is already aware of the non-approved uses of cannabis to treat conditions such as AIDS wasting, epilepsy, neuropathic pain, and several others. The agency has also approved one cannabis-derived drug product: Epidiolex (cannabidiol), used to treat seizures, and three synthetic cannabis-related drug products: Marinol (dronabinol), Syndros (dronabinol), and Cesamet (nabilone), all of which treat nausea due to chemotherapy. These approvals don’t signal a trend toward legalization of cannabis, but they do show that the FDA’s studies of cannabis are starting to bear some fruit.

The most recent official guidance from the FDA regarding cannabis regulation was published in January 2021. In this communication, the FDA reassured readers that they are aware of the public interest in using cannabis to develop treatments and consumer products. But the FDA is known for being cautious. The stakes for getting it wrong are high when measured in lives lost. To make matters more complicated, the public is divided on the benefits and dangers of cannabis. However, with other countries experimenting with or outright approving cannabis, the FDA is clearly feeling the pressure to move on the issue of cannabis regulation in the United States.

This CLE will discuss the FDA’s current stance and what needs to happen to move the needle on the FDA’s regulation of cannabis. The discussion will be led by a panel of three cannabis regulation experts. Amber Littlejohn will serve as moderator. Littlejohn is the executive director of the Minority Cannabis Business Association in Washington, D.C., and director of the U.S. Hemp Authority. Patrick Goggin and Garrett Graff will round out the panel. Goggin is a Senior Attorney with the Hoban Law Group specializing in assisting both large and small cannabis businesses. Graff is a partner is Moye White LLP and nationally recognized as a Cannabis Law Trailblazer by National Law Journal.

This program is a must for anyone in the professional cannabis business who is eagerly awaiting FDA regulation and all the changes that come with it.


The Future of FDA and Cannabis Regulation


Popular posts from this blog

Cannabis Branding: On the Edge of the Metaverse

Photo by julien Tromeur on Unsplash Branding in the Metaverse is all the rage. In the last three months alone, well-known brands like Nike, Converse, New Balance, Vineyard Vines, Tahari, Anthropologie, Hollister, Abercrombie & Fitch, and, even Walmart, have all filed applications with the United States Patent and Trademark Office  for intent-to-use trademarks in connection with “digital goods;”# opportunistic filings by individuals not affiliated with name brands have appeared in Classes 9, 35, and 41# for both PRADA and GUCCI; and Metaverse Law, a clever California law firm has been diligently going through the motions in their attempt to trademark the very word on everyone’s lips. But what is Metaverse, and why should you, the owner of the expertly cultivated flower brand, or producer of the most delicately infused edibles care? Metaverse is a virtual world meant to support decentralized, persistent three-dimensional environments, and accessible by anyone with a smart phone, gam

Diversity in the Cannabis Industry - it's more than checking the box

  June 30, 2022 12:30-2PM Eastern/11:30AM-1PM Central CICK HERE TO REGISTER Discover what your clients are missing about diversity in the cannabis industry – including how to address issues unique to this industry. You will hear from a diverse panel of cannabis business owners and executives about their experiences and learn tips for keeping your clients on the right side of this issue. Prep for this with this article from Marijuana Business Journal found in The Cannabis NewsHub . We are proud to be content providers and supporters of ABA Moderator:   Susan Burns , S Burns Legal PLLC Panelists: Steven Brown , CEO, Nothing But Hemp LLC Angela Dawson , CEO and co-founder, 40 Acres Co-op Amber Littlejohn , Executive Director, Minority Cannabis Business Association Maggie May Wilson , CMO, Fruit Slabs Lici Zimmerman Co-Sponsored by the ABA TIPS Cannabis Committee

DOES NEW YORK HAVE A RESIDENCY REQUIREMENT FOR CANNABIS LICENSEES?

  By Andrew Kingsdale (published here with permission) Originally published February 3, 2022 on the blog of the Law Offices of Omar Figueroa Does one have to be a New York resident to own or manage a New York state-licensed cannabis business?  No, but the license applicant does need to have a certain nexus to the state.  With certain exceptions, non-residents may use a business or other legal entity to satisfy the nexus requirements. We start with definition of an “applicant”under New York’s new cannabis law, the Marijuana Regulation and Taxation Act (MRTA): “Applicant” unless otherwise specified in this chapter, shall mean a person applying for any cannabis, medical cannabis or cannabinoid hemp license or permit issued by the New York state cannabis control board pursuant to this chapter that: has a significant presence in New York state, either individually or by having a principal corporate location in the state; is incorporated or otherwise organized under the laws of this state; o

INCBA Ethics Committee Offers Suggested Model Rule Revision to ABA

  This week INCBA’s Professional Responsibility and Ethics Committee commented to the ABA regarding a proposed change to the Model Rules for client due diligence , and committee member Joslin Monahan spoke on behalf of INCBA at an ABA roundtable for the same.   INCBA proposed modifying Model Rule 1.2(d) and offered a comment to Rule 1.6 , both designed to promote that cannabis lawyers – and other attorneys dealing with dual sovereignty conflicts – are able to advise and represent their legal cannabis clients, and ensure attorney-client privilege with the same, without fear of discipline merely for assisting their clients in following the law. Quick Links: INCBA Request for Comment Support INCBA Ethics Hotline

INCBA Europe Conference at CB Expo in Zurich 2022 – a great success!

  On the weekend of September 10th, INCBA hosted the first ever Conference for Cannabis Lawyers in Europe at the CB Expo. Over the course of two days, seventeen attorneys from Europe and the US presented seven sessions on the main legal issues facing the European cannabis market. Topics included the principle of free movement of hemp and cannabis products within the EU, the legal classification of CBD products as food or cosmetics, contractual aspects of importing cannabis products into the EU, the legal hurdles in the legalization of recreational cannabis, and much more. The active and participatory audience included both lawyers as well as interested entrepreneurs who could take away valuable insights for their businesses. In addition to the unparalleled education, there was plenty of networking to be found, including the social reception at Cannavigia sponsored by INCBA on the eve of the conference, at the after-party of the conference itself, or at the closing dinner with INCBA Lea